title: "Real world" outcome of lenalidomide plus dexamethasone in the setting of recurrent and refractory multiple myeloma: extended follow-up of a retrospective multicenter study by the "rete ematologica pugliese".
abstract: This current retrospective multicenter analysis represents, to our knowledge, the first Italian study evaluating the efficacy and toxicity profile of "lenalidomide plus dexamethasone" as salvage therapy in patients with recurrent-refractory MM in the real life contest. Our study included patients who are usually excluded from clinical trials because of unfavorable baseline characteristics. Median OS was significantly longer in patients receiving "lenalidomide plus dexamethasone" for more than 12 months compared with those who had received "lenalidomide plus dexamethasone" for a shorter interval (P<0.0001). Median OS was not affected by best response achieved (P 0.4) and age (P 0.3). Quality of response did not correlate with number of previous lines of therapy (P 0.77) and age. Higher ORRs were recorded in the patients group with relapsed MM compared to those with refractory disease, but this difference was not statistically significant (P 0.38).
authors: Haematology, Ospedale A. Perrino, Brindisi, Italy. Electronic address: giuseppemele2007@gmail.com.
authors: G
authors: G
authors: Mele
authors: Haematology, Ospedale A. Perrino, Brindisi, Italy.
authors: A
authors: A
authors: Melpignano
authors: Haematology, Ospedale A. Perrino, Brindisi, Italy.
authors: G
authors: G
authors: Quarta
authors: Haematology, Ospedali Riuniti, Foggia, Italy.
authors: G
authors: G
authors: Palumbo
authors: Haematology, Ospedali Riuniti, Foggia, Italy.
authors: S
authors: S
authors: Capalbo
authors: Haematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy.
authors: A
authors: A
authors: Falcone
authors: Haematology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy.
authors: N
authors: N
authors: Cascavilla
authors: Haematology, Ospedale G. Moscati, Taranto, Italy.
authors: G
authors: G
authors: Palazzo
authors: Haematology, Ospedale G. Moscati, Taranto, Italy.
authors: P
authors: P
authors: Mazza
authors: Haematology, Ospedale G. Moscati, Taranto, Italy.
authors: E
authors: E
authors: Iannitto
authors: Haematology, University of Bari Medical School, Policlinico, Bari, Italy.
authors: P
authors: P
authors: Curci
authors: Haematology, University of Bari Medical School, Policlinico, Bari, Italy.
authors: R
authors: R
authors: Rizzi
authors: Haematology, University of Bari Medical School, Policlinico, Bari, Italy.
authors: G
authors: G
authors: Specchia
authors: Haematology, Ospedale Cardinale Panico, Tricase, Lecce, Italy.
authors: B
authors: B
authors: Rossini
authors: Haematology, Ospedale Cardinale Panico, Tricase, Lecce, Italy.
authors: V
authors: V
authors: Pavone
authors: Internal Medicine, University of Bari Medical School, Policlinico, Bari, Italy.
authors: R
authors: R
authors: Ria
authors: Internal Medicine, University of Bari Medical School, Policlinico, Bari, Italy.
authors: A
authors: A
authors: Vacca
authors: Haematology, Ospedale Monsignor R. Dimiccoli, Barletta, Bari, Italy.
authors: C
authors: C
authors: Buquicchio
authors: Haematology, Ospedale Monsignor R. Dimiccoli, Barletta, Bari, Italy.
authors: G
authors: G
authors: Tarantini
authors: Haematology, Ospedale Giovanni Paolo II, Bari, Italy.
authors: C
authors: C
authors: Minoia
authors: Haematology, Ospedale Giovanni Paolo II, Bari, Italy.
authors: A
authors: A
authors: Guarini
authors: Haematology, Ospedale Di Venere, Bari, Italy.
authors: P
authors: P
authors: Ditonno
authors: Haematology, Ospedale F. Miulli, Acquaviva delle Fonti, Bari, Italy.
authors: G
authors: G
authors: Polimeno
authors: Haematology, Ospedale V. Fazzi, Lecce, Italy.
authors: G
authors: G
authors: Reddiconto
authors: Haematology, Ospedale V. Fazzi, Lecce, Italy.
authors: N
authors: N
authors: Di Renzo
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D000077269:Lenalidomide; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D016879:Salvage Therapy; D015996:Survival Rate; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D013792:Thalidomide; D003907:Dexamethasone; D000077269:Lenalidomide
keywords: Continuous treatment; Heavily pre-treated patients; Lenalidomide plus dexamethasone; Refractory/recurrent myeloma; Very elderly patients